SCHEMBL799359

SCHEMBL799359

COc1cncc(-c2cc(NC(=O)Nc3ccccc3C(=O)NC(C)C)nn2C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
POLB P06746 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
ADORA2B P29275 2/20 0.39
ADORA1 P30542 2/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
PKM P14618 3/20 0.39
ABCG2 Q9UNQ0 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPK1 P28482 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798969 0.84 MAPK1 (0.43) ALDH1A1KDM4EHTTSMN1; SMN2HSD17B10
SCHEMBL798739 0.81 KDM4E (0.41) ALDH1A1KDM4ESMN1; SMN2ADORA2BADORA1
SCHEMBL798614 0.80 PDE4A (0.45) ALDH1A1POLBCYP1A2CYP3A4CYP2C9
SCHEMBL171590 0.79 RIPK1 (0.48)
SCHEMBL805085 0.71 ALDH1A1 (0.40) ALDH1A1POLBCYP1A2CYP3A4CYP2C9
SCHEMBL799139 0.70 RIPK1 (0.48) KDM4EHTTMEN1KMT2A
SCHEMBL10392 0.67 PIK3CG (0.51) CYP2C9
SCHEMBL29614706 0.67 KDM4E (0.53) ALDH1A1POLBCYP1A2CYP3A4KDM4E
SCHEMBL19307111 0.67 KDM4E (0.53) ALDH1A1POLBCYP1A2CYP3A4KDM4E
SCHEMBL799302 0.65 RIPK1 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 ALDH1A1 3750/4885POLB 1335/4885CYP1A2 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.